EP0239289A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Novel pharmaceutical combinations
Assignee: Wellcome Foundation Ltd
•
Filing: 1987-03-12
•
Granted: —
•
Expires: 2007-03-12
Abstract
Abstract A combination of t-PA and oxypurinol of use in inhibiting damage to jeopardized tissue during reperfusion in a mammal.
Inventors
- 👤 Donald H. Namm
- 👤 Thomas Spector
- 👤 Henry Berger, Jr.
- 👤 Crist J. Frangakis
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 20:44
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
12 words
A combination of t-PA and oxypurinol, or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
12 words
A combination of t-PA and oxypurinol, or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
14 words
A combination according to claim 1, wherein the t-PA is in the one-chain form.
Claim 4
Dependent Claim
14 words
A combination according to claim 1, wherein the t-PA is in the two-chain form.
Claim 5
Dependent Claim
70 words
A combination according to any one of the preceding claims, wherein the t-PA has the amino acid sequence set forth in Figure 1 or has the same amino acid sequence but with the amino acid in the 245th position from the serine N-terminus being valine instead of methionine, either sequence optionally being without any of the first three amino acids or optionally having an additional polypeptide N-terminal presequence of Gly-Ala-Arg.
Claim 6
Dependent Claim
21 words
A combination according to any one of the preceding claims, wherein the pharmaceutically acceptable salt of oxypurinol is the sodium salt.
Claim 7
Dependent Claim
20 words
A pharmaceutical formulation, which comprises a combination according to any one of the preceding claims and a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
18 words
A combination according to any one of claims 1 to 5 for use in human and veterinary medicine.
Claim 9
Dependent Claim
20 words
A combination according to claim 7 for use in inhibiting damage to jeopardized tissue during blood reperfusion in a mammal.
Claim 10
Dependent Claim
25 words
A combination according to claim 7 for use in the removal of a blood clot and in inhibiting damage to jeopardized tissue during blood reperfusion.
Claim 11
Dependent Claim
29 words
Use of t-PA and oxypurinol, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for inhibiting damage to jeopardized tissue during blood reperfusion in a mammal.
Claim 12
Dependent Claim
29 words
Use of t-PA and oxypurinol, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for inhibiting damage to jeopardized tissue during blood reperfusion in a mammal.
Claim 13
Dependent Claim
37 words
Use of t-PA and oxypurinol, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the removal of a blood clot and for inhibiting damage to jeopardized tissue during blood reperfusion in a mammal.
Claim 14
Dependent Claim
37 words
Use of t-PA and oxypurinol, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the removal of a blood clot and for inhibiting damage to jeopardized tissue during blood reperfusion in a mammal.
References Cited (Backward Citations)
WO1986001104A1
Cited
WO1986001110A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.